REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
RGX-202 in Duchenne muscular dystrophy on track for topline results 1H 2026 and BLA submission mid-2026 Pivotal trial enrollment accelerated, expected to complete in October 2025 ahead of previous ...
How might the market react to the company's ability to meet or exceed the accelerated timelines versus its previous guidance?
What are the potential partnership or licensing opportunities that could arise from the successful development of RGX‑202 and RGX‑121?
How does the current financial performance (e.g., net loss, R&D spend) compare to peers in the gene‑therapy space?
21 days ago